Francisco Espana

Summary

Country: Spain

Publications

  1. ncbi Changes in molecular forms of prostate-specific antigen during treatment with finasteride
    F Espana
    Research Center and Department of Urology, La Fe University Hospital, Valencia, Spain
    BJU Int 90:672-7. 2002
  2. ncbi Low level of circulating activated protein C is a risk factor for venous thromboembolism
    F Espana
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 86:1368-73. 2001
  3. ncbi The role of protein C inhibitor in human reproduction
    Francisco Espana
    Hospital Universitario La Fe, Centro de Investigacion, Valencia, Spain
    Semin Thromb Hemost 33:41-5. 2007
  4. ncbi The multifunctional protein C system
    F Espana
    Hospital Universitario La Fe, Centro de Investigacion, Av Campanar 21, 46009 Valencia, Spain
    Curr Med Chem Cardiovasc Hematol Agents 3:119-31. 2005
  5. ncbi Inherited abnormalities in the protein C activation pathway
    Francisco Espana
    Research Center, La Fe University Hospital, Valencia, Spain
    Pathophysiol Haemost Thromb 32:241-4. 2002
  6. ncbi Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation
    Silvia Navarro
    Research Center, La Fe University Hospital, Valencia, Spain
    Haematologica 93:885-91. 2008
  7. ncbi Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden
    Pilar Medina
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 94:389-94. 2005
  8. ncbi Haplotypes of the endothelial protein C receptor gene and Behçet's disease
    Silvia Navarro
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 129:459-64. 2012
  9. ncbi Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression
    Luis A Ramon
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 122:854-60. 2008
  10. ncbi Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis
    Jose M Ricart
    Dermatology Service, La Fe University Hospital, Valencia, Spain
    Br J Haematol 141:716-9. 2008

Collaborators

Detail Information

Publications34

  1. ncbi Changes in molecular forms of prostate-specific antigen during treatment with finasteride
    F Espana
    Research Center and Department of Urology, La Fe University Hospital, Valencia, Spain
    BJU Int 90:672-7. 2002
    ..To study the influence of finasteride treatment on the molecular forms of prostate-specific antigen (PSA) in patients with benign prostatic hyperplasia (BPH)...
  2. ncbi Low level of circulating activated protein C is a risk factor for venous thromboembolism
    F Espana
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 86:1368-73. 2001
    ..We conclude that a low level of circulating APC in individuals without any of the most recognized thrombophilic defects is a prevalent, independent risk factor for VTE, and that it predisposes to recurrent VTE...
  3. ncbi The role of protein C inhibitor in human reproduction
    Francisco Espana
    Hospital Universitario La Fe, Centro de Investigacion, Valencia, Spain
    Semin Thromb Hemost 33:41-5. 2007
    ..05 microM of PCI, fertilization rates might be significantly reduced. All of these data suggest that PCI is involved in human reproduction at several steps, including the fertilization process...
  4. ncbi The multifunctional protein C system
    F Espana
    Hospital Universitario La Fe, Centro de Investigacion, Av Campanar 21, 46009 Valencia, Spain
    Curr Med Chem Cardiovasc Hematol Agents 3:119-31. 2005
    ..This review will summarize the mechanisms that contribute to these biological activities of the protein C pathway...
  5. ncbi Inherited abnormalities in the protein C activation pathway
    Francisco Espana
    Research Center, La Fe University Hospital, Valencia, Spain
    Pathophysiol Haemost Thromb 32:241-4. 2002
    ..Here, we describe the previously reported mutations in the TM and EPCR genes, and present the design and evaluation of a new strategy to investigate TM, EPCR, PC and prothrombin gene mutations in arterial and venous thrombosis...
  6. ncbi Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation
    Silvia Navarro
    Research Center, La Fe University Hospital, Valencia, Spain
    Haematologica 93:885-91. 2008
    ..We assessed whether these haplotypes modify the risk of venous thromboembolism in carriers of the prothrombin 20210A allele...
  7. ncbi Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden
    Pilar Medina
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 94:389-94. 2005
    ....
  8. ncbi Haplotypes of the endothelial protein C receptor gene and Behçet's disease
    Silvia Navarro
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 129:459-64. 2012
    ..Thus, the objective of this study was to evaluate the influence of these haplotypes on the thrombosis risk in Behçet's disease...
  9. ncbi Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression
    Luis A Ramon
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 122:854-60. 2008
    ....
  10. ncbi Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis
    Jose M Ricart
    Dermatology Service, La Fe University Hospital, Valencia, Spain
    Br J Haematol 141:716-9. 2008
    ..024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients...
  11. ncbi Endothelial protein C receptor polymorphisms and risk of myocardial infarction
    Pilar Medina
    Hospital Universitario La Fe, Centro de Investigacion, Av Campanar 21, 46009 Valencia, Spain
    Haematologica 93:1358-63. 2008
    ..We assessed whether these haplotypes modify the risk of premature myocardial infarction...
  12. ncbi Vascular endothelial growth factor polymorphisms (-460C/T, +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression
    Raúl Cosín
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Fertil Steril 92:1214-20. 2009
    ....
  13. ncbi Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis
    Amparo Vaya
    Hemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Avda Campanar 21, Valencia 46009, Spain
    Thromb Haemost 98:621-6. 2007
    ..Our results suggest that increased EA constitute an independent risk factor for DVT. However, when associated to hyperlipidaemia and obesity it further increases thrombotic risk...
  14. ncbi Erythrocyte membrane phosphatidylserine exposure in obesity
    Eva Sola
    Endocrinology Service, Doctor Peset University Hospital, Valencia, Spain
    Obesity (Silver Spring) 17:318-22. 2009
    ..Increased PS exposure could contribute to hypercoagulability in these patients. Weight loss obtained with diet treatment reduces PS exposure on erythrocyte membrane...
  15. ncbi Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer
    Remedios Castello
    Hospital Universitario La Fe, Centro de Investigacion, Avda Campanar 21, 46009 Valencia, Spain
    Clin Chem 48:1288-95. 2002
    ..The plasminogen activation system and matrix metalloproteinases (MMPs) play a key role in the degradation of basement membrane and extracellular matrix in tissue remodeling, cancer cell invasion, and metastasis...
  16. ncbi Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels
    Pilar Medina
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 107:448-57. 2012
    ..Furthermore, a sufficiently carboxylated PC Gla-domain seems to be essential for PC activation in vivo...
  17. ncbi Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk
    Pilar Medina
    Research Center, La Fe University Hosptial, Valencia, Spain
    Thromb Haemost 91:905-11. 2004
    ....
  18. ncbi Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events
    Jose Ma Ricart
    Dermatology Service, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 95:618-24. 2006
    ..When studies from Turkey were excluded from the meta-analysis, only the prothrombin G20210A mutation was associated with thrombosis...
  19. ncbi Obesity and activated protein C resistance
    Eva Sola
    Endocrinology Department, Doctor Peset University Hospital, School of Medicine, Valencia University, Valencia, Spain
    Pathophysiol Haemost Thromb 36:64-8. 2008
    ..After weight loss, prothrombin fragment F1 + 2 was reduced, but no differences were found in activated protein C sensitivity. We did not find an activated protein C-resistant phenotype in obese subjects...
  20. ncbi Polymorphisms in the endothelial protein C receptor gene and thrombophilia
    Pilar Medina
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 98:564-9. 2007
    ..This review highlights the different mutations/polymorphisms reported in the EPCR gene and their association with the risk of thrombosis...
  21. ncbi Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer
    Remedios Castello
    Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 120:753-62. 2007
    ..Increased levels of uPA and PAI-1 are known to be associated with a poor prognosis in breast cancer. To our knowledge this is the first study of the expression and role of PAI-3 in human breast cancer tissue...
  22. ncbi The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L
    Manuel Martinez
    Department of Urology, Research Center, La Fe University Hospital, 46009 Valencia, Spain
    Clin Chem 48:1251-6. 2002
    ....
  23. ncbi Fibrinolysis: the key to new pathogenetic mechanisms
    Esther Zorio
    Hospital Universitario La Fe, Centro de Investigacion, Servicio de Cardiología y Servicio de Ginecología Valencia, Spain
    Curr Med Chem 15:923-9. 2008
    ....
  24. ncbi Activated protein C levels in obesity and weight loss influence
    Eva Sola
    Endocrinology Service, Doctor Peset University Hospital, Valencia, Spain
    Thromb Res 123:697-700. 2009
    ..Activated protein C levels decrease with weight loss, due in part to a thrombin generation reduction...
  25. ncbi microRNAs expression in endometriosis and their relation to angiogenic factors
    Luis A Ramon
    Research Center, Hospital Universitario La Fe, Valencia, Spain
    Hum Reprod 26:1082-90. 2011
    ....
  26. ncbi Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity
    Remedios Castello
    Hospital Universitario La Fe, Centro de Investigación Avda Campanar 21, 46009 Valencia, Spain
    Thromb Res 117:487-92. 2006
    ..In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer...
  27. ncbi microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer
    Luis A Ramon
    Research Center Anatomopathology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
    Hum Reprod 27:3036-45. 2012
    ..None of the authors have any conflicts of interest...
  28. ncbi Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity
    Juan Gilabert-Estelles
    Gynecology Service, Hospital Universitario Dr Peset, Valencia, Spain
    Thromb Res 130:242-7. 2012
    ..Further studies with a larger number of patients are needed to clarify the influence of this PAI-1 polymorphism in endometrial cancer...
  29. ncbi The endothelial cell protein C receptor: its role in thrombosis
    Silvia Navarro
    Hemostasis and Thrombosis Unit, Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Res 128:410-6. 2011
    ..This review highlights the role of the endothelial protein C receptor in disease and discusses the association of its mutations with the risk of thrombosis...
  30. ncbi The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population
    Amparo Vaya
    Hemostasis Unit, Service of Clinical Pathology, La Fe University Hospital, Avenida de Campanar 21, Valencia, Spain
    Metab Syndr Relat Disord 9:197-201. 2011
    ..We aimed to evaluate the impact of metabolic syndrome and its individual components on VTE risk...
  31. ncbi The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer
    Manuel Martinez
    Department of Urology, La Fe University Hospital, Valencia, Spain
    Eur Urol 43:609-14. 2003
    ....
  32. ncbi Plasminogen activators and plasminogen activator inhibitors in endometriosis
    Juan Gilabert-Estelles
    Department of Gynecology (Human Reproduction, Hospital Universitario La Fe, Valencia, Spain
    Front Biosci 10:1162-76. 2005
    ..The aim of the present study is to review the role of the plasminogen activator system in endometriosis, consider the clinical implications and focus on possible further research efforts and therapeutic applications in this disease...
  33. ncbi Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors
    Amparo Vaya
    Thrombosis and Hemostasis Unit, Department of Clinical Pathology, Thrombosis Research Center, La Fe University Hospital, Valencia, Spain
    Br J Haematol 118:255-9. 2002
    ..In addition, cholesterolaemia levels of >or= 5.69 mmol/l constitute an independent risk factor for idiopathic DVT...
  34. ncbi Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo
    M Geiger
    Department of Medical Physiology, University of Vienna, Austria
    Blood 74:722-8. 1989
    ..These data suggest that at high uPA concentrations, such as during uPA therapy, plasma PCI might contribute significantly to uPA inhibition in vivo...